Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.3 USD | -5.91% | -12.24% | +159.04% |
May. 07 | HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating | MT |
May. 06 | Rate Cut Hopes Lift Exchange-Traded Funds, Equity Futures Pre-Bell Monday | MT |
Business Summary
Number of employees: 274
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Antibody Drug Conjugates
100.0
%
| 210 | 100.0 % | 70 | 100.0 % | -66.86% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ameet Mallik
CEO | Chief Executive Officer | 51 | 22-05-08 |
Jose Carmona
DFI | Director of Finance/CFO | 51 | 22-12-18 |
Mohamed Zaki
CTO | Chief Tech/Sci/R&D Officer | 59 | 23-01-02 |
Chief Tech/Sci/R&D Officer | 55 | 12-07-31 | |
Chief Tech/Sci/R&D Officer | 69 | 22-10-31 | |
Corporate Officer/Principal | 51 | 22-11-16 | |
Kimberly Pope
HRO | Human Resources Officer | 57 | 20-08-16 |
Peter J. Graham
LAW | General Counsel | 57 | 22-10-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Peter Hug
BRD | Director/Board Member | 65 | 19-05-31 |
Ron Squarer
CHM | Chairman | 57 | 20-03-31 |
Jean Bizzari
BRD | Director/Board Member | 69 | 22-06-30 |
Ameet Mallik
CEO | Chief Executive Officer | 51 | 22-05-08 |
Victor Sandor
BRD | Director/Board Member | 57 | 20-04-26 |
Robert Azelby
BRD | Director/Board Member | 56 | 23-06-13 |
Thomas Pfisterer
BRD | Director/Board Member | 42 | 16-09-30 |
Tyrell J. Rivers
BRD | Director/Board Member | 51 | 18-05-31 |
Viviane Monges
BRD | Director/Board Member | 60 | 21-06-10 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 102,453,858 | 76,151,847 ( 74.33 %) | 6,264,720 ( 6.115 %) | 74.33 % |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+159.04% | 414M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ADCT Stock
- Company ADC Therapeutics SA